Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary Origin - Falkson, Carla I.; Cohen, G.L. (Oncology, 1998)
Keywords: Adenocarcinoma - drug therapy; Adenocarcinoma - secondary; Adult; Aged; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - adverse effects; Antibiotics, Antineoplastic - therapeutic use; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - pharmacology; Clinical Study; Disease-Free Survival; Epirubicin - administration & dosage; Epirubicin - pharmacology; Female; Humans; Male; Medical sciences; Middle Aged; Mitomycin - administration & dosage; Mitomycin - adverse effects; Mitomycin - pharmacology; Mitomycin - therapeutic use; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Neoplasms, Unknown Primary - drug therapy; Pharmacology. Drug treatments; Prospective Studies; Survival Analysis; Treatment Outcome; Tumors; Carcinoma, unknown primary; Mitomycin C; Epirubicin; Cisplatin; Antineoplastic agent; Human; Carcinoma; Mitomycin; Treatment efficiency; Multivariate analysis; Chemotherapy; Clinical trial; Anthracyclins; Therapeutic protocol; Survival curve; Comparative study; Platinum II Complexes